Ayal A Aizer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6674064/publications.pdf

Version: 2024-02-01

118 papers	5,594 citations	94269 37 h-index	85405 71 g-index
120 all docs	120 docs citations	120 times ranked	8152 citing authors

#	Article	IF	Citations
1	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	0.6	83
2	Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: a population- and institutional-level analysis. Neuro-Oncology Practice, 2022, 9, 114-122.	1.0	1
3	Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. Physics in Medicine and Biology, 2022, 67, 065009.	1.6	2
4	Predictors of long-term survival among patients with brain metastases. Neuro-Oncology, 2022, , .	0.6	2
5	Trends in location of death for individuals with primary brain tumors in the United States. Neuro-Oncology, 2022, 24, 1400-1401.	0.6	2
6	Incidence and Predictors of Neurologic Death in Patients with Brain Metastases. World Neurosurgery, 2022, 162, e401-e415.	0.7	2
7	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. Journal of Neuro-Oncology, 2022, 157, 499-510.	1.4	2
8	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	0.6	39
9	Salvage brachytherapy for multiply recurrent metastatic brain tumors: A matched case analysis. Neuro-Oncology Advances, 2022, 4, vdac039.	0.4	0
10	Population-based estimates of survival among elderly patients with brain metastases. Neuro-Oncology, 2021, 23, 661-676.	0.6	25
11	Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. European Radiology, 2021, 31, 4114-4129.	2.3	22
12	Seizures Among Patients With Brain Metastases. Neurology, 2021, 96, .	1.5	12
13	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. Medical Dosimetry, 2021, 46, 21-28.	0.4	4
14	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean Journal of Radiology, 2021, 22, 584.	1.5	12
15	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Network Open, 2021, 4, e213304.	2.8	4
16	Epidemiology of brain metastases and leptomeningeal disease. Neuro-Oncology, 2021, 23, 1447-1456.	0.6	123
17	Is radiation necrosis in radiated melanoma brain metastasis increasing because immunotherapy is contributing to this or are patients just living longer?. Journal of Clinical Oncology, 2021, 39, e21518-e21518.	0.8	0
18	Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Neuro-Oncology Practice, 2021, 8, 569-580.	1.0	1

#	Article	IF	Citations
19	Surgical and Peri-Operative Considerations for Brain Metastases. Frontiers in Oncology, 2021, 11, 662943.	1.3	15
20	Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiotherapy and Oncology, 2021, 160, 159-165.	0.3	67
21	Long-term Overall Survival and Predictors in Antiâ€“PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. Journal of Immunotherapy, 2021, 44, 307-318.	1.2	4
22	The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases. Neuro-Oncology, 2021, 23, 1816-1817.	0.6	3
23	Development of Brain Metastases in Patients With Nonâ€“Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis. American Journal of Roentgenology, 2021, 217, 1184-1193.	1.0	13
24	NEIM-04. PROSPECTIVE STUDY OF SCREENING MRI OF THE BRAIN IN PATIENTS WITH METASTATIC OR INFLAMMATORY BREAST CANCER. Neuro-Oncology Advances, 2021, 3, iv7-iv7.	0.4	0
25	Identification and Characterization of Leptomeningeal Metastases Using SPINE, A Webâ€Based Collaborative Platform. Journal of Neuroimaging, 2021, 31, 324-333.	1.0	3
26	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. World Neurosurgery, 2020, 133, e804-e812.	0.7	4
27	Utility of claims data for identification of date of diagnosis of brain metastases. Neuro-Oncology, 2020, 22, 575-576.	0.6	12
28	A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR+/HER2â^' Metastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, e232-e243.	1.1	29
29	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.4	0
30	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for nonâ€“small cell lung cancer and melanoma brain metastases. Cancer, 2020, 126, 5274-5282.	2.0	19
31	Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Neuro-Oncology, 2020, 22, 1547-1548.	0.6	2
32	Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncology, 2020, 6, 1972.	3.4	22
33	Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Nonâ€“Small Cell Lung Cancer. Radiology, 2020, 297, 419-427.	3.6	21
34	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology, 2020, 38, 3773-3784.	0.8	223
35	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurgery, 2020, 139, 226-231.	0.7	5
36	Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology, 2020, 6, 1028.	3.4	122

#	Article	IF	Citations
37	Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. Journal of Neuro-Oncology, 2020, 148, 509-517.	1.4	7
38	Hospice Utilization in Elderly Patients With Brain Metastases. Journal of the National Cancer Institute, 2020, 112, 1251-1258.	3.0	7
39	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. Neuro-Oncology, 2020, 22, 1339-1347.	0.6	27
40	A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2â€“ Metastatic Breast Cancer. International Journal of Breast Cancer, 2020, 2020, 1-16.	0.6	33
41	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	0.6	49
42	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.4	81
43	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. Neuro-Oncology, 2020, 22, ii43-ii44.	0.6	3
44	Bilateral occipital metastases: Visual deficits and management considerations. , 2020, 11, 428.		1
45	Alcohol Use Among Patients With Cancer and Survivors in the United States, 2000â€“2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 69-79.	2.3	29
46	Molecular Taxonomy of Meningioma. , 2020, 81, .		0
47	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2020, 22, ii44-ii44.	0.6	5
48	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii228-ii228.	0.6	0
49	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. Neuro-Oncology, 2020, 22, ii186-ii187.	0.6	0
50	NCOG-09. EFFICACY OF HER2-TARGETED ANTIBODY THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS. Neuro-Oncology, 2020, 22, ii131-ii131.	0.6	0
51	Prevalence of chronic pain among cancer survivors in the United States, 2010â€2017. Cancer, 2019, 125, 4310-4318.	2.0	37
52	EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clinical and Translational Radiation Oncology, 2019, 18, 32-38.	0.9	17
53	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clinical and Translational Radiation Oncology, 2019, 18, 39-45.	0.9	26
54	LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. Acta OncolÃ³gica, 2019, 58, 1275-1282.	0.8	50

#	Article	IF	Citations
55	SURG-09. SURGICAL AND PERI-OPERATIVE CONSIDERATIONS FOR BRAIN METASTASES: A NATIONWIDE ANALYSIS. Neuro-Oncology Advances, 2019, 1, i32-i32.	0.4	0
56	MLTI-12. TIMING OF SYSTEMIC THERAPY ADMINISTRATION RELATIVE TO STEREOTACTIC RADIOSURGERY AND DEVELOPMENT OF RADIATION NECROSIS IN PATIENTS WITH BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i16-i17.	0.4	0
57	Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. JAMA Oncology, 2019, 5, e191973.	3.4	12
58	Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. JAMA Network Open, 2019, 2, e193759.	2.8	34
59	Survival and prognostic factors in surgically treated brain metastases. Journal of Neuro-Oncology, 2019, 143, 359-367.	1.4	35
60	Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. JAMA Oncology, 2019, 5, 703.	3.4	63
61	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. Breast Cancer Research and Treatment, 2019, 176, 171-179.	1.1	15
62	Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States. JAMA Oncology, 2019, 5, 735.	3.4	44
63	A low percentage of metastases in deep brain and temporal lobe structures. Neuro-Oncology, 2019, 21, 640-647.	0.6	8
64	Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. Cancer Medicine, 2019, 8, 13-20.	1.3	55
65	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. Journal of Neuro-Oncology, 2019, 142, 355-363.	1.4	13
66	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	2.2	13
67	Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017. JAMA Oncology, 2019, 5, 426.	3.4	22
68	EPID-22. NEWLY-DIAGNOSED BRAIN TUMORS IN PEDIATRIC PATIENTS: EPIDEMIOLOGY IN THE UNITED STATES. Neuro-Oncology, 2019, 21, vi79-vi79.	0.6	0
69	EPID-21. THE NATIONAL SPECTRUM OF NEWLY-DIAGNOSED BRAIN TUMORS IN ADULT PATIENTS VARIES SIGNIFICANTLY BY PATIENT DEMOGRAPHICS. Neuro-Oncology, 2019, 21, vi79-vi79.	0.6	0
70	Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Current Medical Research and Opinion, 2019, 35, 73-80.	0.9	20
71	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. International Journal of Radiation Oncology Biology Physics, 2019, 103, 142-151.	0.4	118
72	The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clinical Cancer Research, 2019, 25, 2656-2663.	3.2	42

#	Article	IF	Citations
73	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. World Neurosurgery, 2019, 122, e1557-e1561.	0.7	17
74	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus, 2019, 5, 474-481.	1.6	44
75	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus, 2019, 11, e4726.	0.2	2
76	Meningioma transcription factors link cell lineage with systemic metabolic cues. Neuro-Oncology, 2018, 20, 1331-1343.	0.6	9
77	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.3	18
78	Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation. JAMA Oncology, 2018, 4, 1123.	3.4	238
79	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	0.6	13
80	CMET-32. BILATERAL OCCIPITAL METASTASES: MANAGEMENT CONSIDERATIONS AND CORTICAL BLINDNESS. Neuro-Oncology, 2018, 20, vi60-vi61.	0.6	0
81	CMET-07. FRAILTY PREDICTS MORTALITY AFTER RESECTION OF BRAIN METASTASES. Neuro-Oncology, 2018, 20, vi55-vi55.	0.6	0
82	Implications of Screening for Brain Metastases in Patients With Breast Cancer and Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 1001.	3.4	44
83	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research, 2018, 6, 1039-1045.	1.6	60
84	Brain Metastases. Neurologic Clinics, 2018, 36, 557-577.	0.8	24
85	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 344-351.	0.4	143
86	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro-Oncology, 2017, 19, 1511-1521.	0.6	483
87	Whole brain radiotherapy for non-small cell lung cancer. Lancet, The, 2017, 389, 1394-1395.	6.3	2
88	Brain Metastases in Newly Diagnosed Breast Cancer. JAMA Oncology, 2017, 3, 1069.	3.4	224
89	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Journal of Neuro-Oncology, 2017, 135, 581-591.	1.4	15
90	Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer. Neuro-Oncology, 2017, 19, 1015-1016.	0.6	1

#	Article	IF	Citations
91	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiotherapy and Oncology, 2017, 124, 98-103.	0.3	51
92	Non-tunneled versus tunneled dialysis catheters for acute kidney injury requiring renal replacement therapy: a prospective cohort study. BMC Nephrology, 2017, 18, 351.	0.8	26
93	Radiographic Prediction of Meningioma Grade and Genomic Profile. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	1
94	Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS ONE, 2017, 12, e0187908.	1.1	109
95	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. Journal of Neuro-Oncology, 2016, 129, 389-393.	1.4	7
96	Asian Americans and prostate cancer: A nationwide population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e7-233.e15.	0.8	34
97	Association of very low prostateâ€specific antigen levels with increased cancerâ€specific death in men with highâ€grade prostate cancer. Cancer, 2016, 122, 78-83.	2.0	41
98	Glioproliferative Lesion of the Spinal Cord as a Complication of â€œStem-Cell Tourismâ€. New England Journal of Medicine, 2016, 375, 196-198.	13.9	138
99	Genomic landscape of intracranial meningiomas. Journal of Neurosurgery, 2016, 125, 525-535.	0.9	104
100	Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes. Journal of Oral and Maxillofacial Surgery, 2016, 74, 1241-1247.	0.5	68
101	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurgery, 2016, 85, 96-105.	0.7	14
102	Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	0.6	221
103	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
104	Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer, 2015, 121, 4376-4381.	2.0	144
105	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 384-389.	0.4	46
106	Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. Journal of Neuro-Oncology, 2015, 124, 291-297.	1.4	24
107	Cancer-Specific Mortality of Asian Americans Diagnosed With Cancer: A Nationwide Population-Based Assessment. Journal of the National Cancer Institute, 2015, 107, djv054-djv054.	3.0	63
108	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	0.6	40

#	Article	IF	Citations
109	Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1â€“4 brain metastases. Journal of Neuro-Oncology, 2015, 124, 429-437.	1.4	13
110	Lack of reduction in racial disparities in cancerâ€specific mortality over a 20â€year period. Cancer, 2014, 120, 1532-1539.	2.0	204
111	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	0.8	112
112	Medical Oncology Consultation and Minimization of Overtreatment in Men With Low-Risk Prostate Cancer. Journal of Oncology Practice, 2014, 10, 107-112.	2.5	9
113	Cytoreductive nephrectomy in patients with metastatic nonâ€clearâ€cell renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, E67-74.	1.3	62
114	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	0.6	80
115	Marital Status and Survival in Patients With Cancer. Journal of Clinical Oncology, 2013, 31, 3869-3876.	0.8	789
116	Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1364-1372.	2.3	15
117	Should all colorectal cancer patients over age 60 be screened for prostate cancer?. Oncology, 2013, 27, 1032-8.	0.4	0
118	A tale of two tumors: pediatric and adult medulloblastoma. Oncology, 2012, 26, 1095-7.	0.4	0